Abstract
Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and currently there are no approved drugs for treatment. Rationale: We have shown Interleukin 32 (IL32) is upregulated in the liver of individuals at risk for NAFLD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
